Last update July 3, 2022

Desvenlafaxine Succinate

Compatible

Safe substance and/or breastfeeding is the best option.

It is a reuptake-inhibitor of Serotonin and Norepinephrine, and active metabolite of Venlafaxine. Oral administration once a day.

It is excreted in low amount into breast milk. (Ilett 2010, Rampono 2004).

The amount detected in the infant's plasma is in the range of 2% - 6% respective to the amount found in the mother's plasma. (Ilett 2010, Rampono 2004).

Not relevant side-effects have been found in such infants. (Keightley 2020, Rampono 2004)

It is very rare that it causes increased prolactin levels and/or galactorrhea. (Tourian 2011)

Various medical societies and expert consensus consider the use of this medication compatible with breastfeeding. (Hale, Rowe 2013).


See below the information of these related products:

  • Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Venlafaxine Hydrochloride (Safe substance and/or breastfeeding is the best option.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Desvenlafaxine Succinate is also known as


Desvenlafaxine Succinate in other languages or writings:

Groups

Desvenlafaxine Succinate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Desvenlafaxine Succinate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 400 daltons
Protein Binding 30 %
VD 3.4 l/Kg
pKa 10.1 -
Tmax 6 - 7.5 hours
T½ 11 hours
M/P ratio 2.8 -
Theoretical Dose 0.08 - 0.29 mg/Kg/d
Relative Dose 1.5 - 7.8 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Keightley P, Schmidt Sotomayor N, O'Hara K, McWhinney B, Ungerer JP. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry. 2020 Oct;54(10):1035-1036. Abstract
  3. AEMPS-Pfizer. Desvenlafaxina. Ficha técnica. 2019 Full text (in our servers)
  4. Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of Antidepressants in Breastfeeding Mothers. Breastfeed Med. 2015 Abstract Full text (link to original source) Full text (in our servers)
  5. Pfizer. Desvenlafaxine. Drug Summary. 2014 Full text (in our servers)
  6. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  7. Rampono J, Teoh S, Hackett LP, Kohan R, Ilett KF. Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health. 2011 Abstract
  8. Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord. 2011;13(2). pii: PCC.10m00977. Abstract Full text (link to original source)
  9. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S. Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Abstract
  10. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry. 2009 Abstract

Total visits

31,990

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM